Abstract:To the Editor: We appreciate the comments by Levesque and colleagues and that they have brought attention to the consistencies between our data using the genetic Acvr1R206H/+ mouse model of heterotopic ossification (HO) and their model of HO formation in wild-type mice with spinal cord injury (SCI)-induced neurogenic heterotopic ossification (Genet and colleagues1 and Torossian and colleagues2). We agree that together these studies provide strong support for cytokine production by macrophages as a common inducer of HO. We previously have discussed common immunological contributions among multiple HO disorders,3 and the investigations of neurogenic heterotopic ossification (NHO)1, 2 importantly emphasize the role of macrophages and identify the cytokine Oncostatin M in a SCI and injury model that faithfully replicates symptoms of NHO. Our study investigating the role of inflammation in the initiation and development of HO in the rare genetic disorder fibrodysplasia ossifications progressiva (FOP)4 further emphasizes the integral role of inflammation and immune cells in HO pathology. In both our FOP Acvr1R206H/+ model and the NHO/SCI model, cardiotoxin injury to skeletal muscle was used to induce HO. We identified a robust cellular and molecular inflammatory response to injury in our Acvr1R206H model of HO4 with increased presence of innate immune cells, including macrophages and mast cells, as well as increased expression of proinflammatory cytokines, in mutant mice compared to controls. Upon depleting macrophages using clodronate-liposomes—also the same approach used by Genet and colleagues1—we likewise observed a significant decrease in HO formation.4 The relevancy of macrophages and cytokines in the development of HO across multiple disorders is becoming increasingly apparent. In addition to our study and the aforementioned NHO studies, macrophages have been implicated in the development of cardiac HO5 and in a BMP4 overexpression HO model that showed robustly reduced HO formation in response to clodronate-liposome-mediated depletion of macrophages.6 Furthermore, IL-6, a cytokine that we determined to be highly upregulated in Acvr1R206H/+ mutant tissue postinjury and in mast cells,4 has been previously reported as a predictive biomarker for HO development in blast injury patients,7, 8 as noted in our Discussion.4 We also want to highlight the contribution of mast cells to HO development in both FOP and nongenetic HO disorders. Genet and colleagues1 identified Substance P as a secreted factor that was significantly upregulated in human NHO patients, and treatment of their NHO/SCI model with an antagonist of Nk1r (the obligate Substance P receptor) significantly reduced HO volume. Notably, high levels of Substance P have been observed in early lesion biopsies from FOP patients,9 and inhibition of the Substance P neuroinflammatory pathway impaired HO in BMP4 overexpression and BMP2 implant models.9, 10 Our in vivo results showed that genetic ablation of mast cells in Acvr1R206H/+ mutant mice reduced HO volume similarly to macrophage depletion, and that combined depletion of both cell populations resulted in further reduction of HO formation.4 Our group further reported that inhibition of mast cell degranulation by cromolyn reduced HO formation.11 These data support that mast cells are additionally integral to the development of HO. The overlapping inflammatory features among genetic and nongenetic HO disorders has increasingly been confirmed over recent years, and future studies will further clarify commonalities, such as the role of additional cytokines, macrophage polarization, and other immune cell contributions to HO formation. Although it is important to note the unique aspects of FOP pathology, including accelerated cartilage and bone cell differentiation caused by the R206H mutation,12, 13 we fully agree with Levesque and colleagues that the overlapping inflammatory features among genetic and nongenetic HO disorders establishes the immune system as an attractive target for therapeutic intervention for all affected patients. All the authors state that they have no conflicts of interests.

Long-term use of interleukin-1 inhibitors reduce flare activity in patients with fibrodysplasia ossificans progressiva

Immunologic Aspects in Fibrodysplasia Ossificans Progressiva

Characterization of flare-ups and impact of Garetosmab in adults with Fibrodysplasia Ossificans Progressiva: a post hoc analysis of the randomized, double-blind, placebo-controlled LUMINA-1 trial

Effect of interleukin-1 antagonist on growth of children with colchicine resistant or intolerant FMF

Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an Acvr1R206H Mouse Model of Fibrodysplasia Ossificans Progressiva

The serum levels of activin A and bone morphogenetic protein-4 and -6 in patients with fibrodysplasia ossificans progressiva

Anti-ACVR1 antibodies exacerbate heterotopic ossification in fibrodysplasia ossificans progressiva (FOP) by activating FOP-mutant ACVR1

NF-κB/MAPK activation underlies ACVR1-mediated inflammation in human heterotopic ossification

Inflammation in Fibrodysplasia Ossificans Progressiva and Other Forms of Heterotopic Ossification

Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases

How Activin A Became a Therapeutic Target in Fibrodysplasia Ossificans Progressiva

Reply To: Macrophages Driving Heterotopic Ossification: Convergence of Genetically‐Driven and Trauma‐Driven Mechanisms

MMP-9 deficiency confers resilience in Fibrodysplasia Ossificans Progressiva in a man and mice

PI3Kα inhibition blocks osteochondroprogenitor specification and the hyper-inflammatory response to prevent heterotopic ossification

Anti-Interleukin-6 Therapy Decreases Hip Synovitis and Bone Resorption and Increases Bone Formation Following Ischemic Osteonecrosis of the Femoral Head

Cellular and Molecular Mechanisms of Heterotopic Ossification in Fibrodysplasia Ossificans Progressiva

Oxidative phosphorylation is a pivotal therapeutic target of fibrodysplasia ossificans progressiva

Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice with the Human ACVR1R206H Fibrodysplasia Ossificans Progressiva (FOP) Mutation

iMSC-mediated delivery of ACVR2B-Fc fusion protein reduces heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva

Increased Frequency Of Peripheral Blood Il-21(+) Follicular Helper T Cells And Increased Serum Il-21 Levels In Patients With Non-Traumatic Osteonecrosis Of The Femoral Head

Biological and Clinical Changes in a Pediatric Series Treated with Off-Label JAK Inhibitors